Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for a multitude of
reasons including very late diagnosis. This in part is due to the lack of understanding of the …

Objective: To identify predictive factors associated with operative morbidity, mortality, and
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …

Background: Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced
(BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly …

Purpose: To determine whether a multianalyte liquid biopsy can improve the detection and
staging of pancreatic ductal adenocarcinoma (PDAC). Experimental Design: We analyzed …

The value of image based texture features as a powerful method to predict prognosis and
assist clinical management in cancer patients has been established recently. However …

Cancer markers are molecules produced by cancer cells which may serve to identify the
presence of cancer. Cancer markers can be differentiated as serum-based, radiology-based …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer in humans, with a 5‐
year survival rate of< 5%. Recently, glypican‐1 (GPC1)‐expressing circulating exosomes …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a
high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis …